VCC Clinical and Translational Research Symposium Focuses on Epigenetics and Cancer
- By Sarah Lyn Cobleigh Keblin
The Vermont Cancer Center (VCC) at the University of Vermont and Fletcher Allen Health Care is home to a broad spectrum of research, from basic science to clinical research and clinical trials, in the area of epigenetics—an area of cancer research that is at the core of understanding cancer’s early detection, prevention, progression, treatment and survivorship. The VCC invests in collaborative science across disciplines in order to advance research and this year’s annual Clinical and Translational Research Symposium supported that interdisciplinary approach. The symposium tooks place on Thursday, November 8, 2013 at the Davis Auditorium in the UVM College of Medicine and Fletcher Allen Health Care’s Medical Education Center.
This annual symposium provides a comprehensive review and preview of key scientific and medical breakthroughs, as well as new technologies, in the field of oncology, with the goal of maximizing collaboration and progress in research. The day included scientific presentations by guest speakers from around the country, senior investigators at UVM, as well as junior faculty at UVM. In addition there was a poster presentation and competition during lunch.
The event’s afternoon keynote address at 3:50 p.m. -- the J. Walter Juckett Distinguished Lecture -- was presented by Carlo Croce, M.D. of Ohio State University’s James Cancer Hospital and Solove Research Institute.
Sponsored by the Vermont Cancer Center and the Lake Champlain Cancer Research Organization, the event was free to attend.
View the day’s full agenda. Please direct any questions to Charles Brooks.